{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:34:28Z","timestamp":1790091268785,"version":"4.0.1"},"reference-count":60,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The 2025 approval of the selective NaV1.8 blocker suzetrigine for acute pain marked a pivotal advance in analgesic drug development. Yet the subsequent failure of Vertex\u2019s next-generation NaV1.8 inhibitor VX993 to demonstrate clinical analgesia underscores enduring challenges in translating mechanistic promise into patient benefit. This review examines why promising targets and compounds, spanning NaV and TRP channels, often falter and outlines a path toward more reliable target selection and validation. I first summarize the pain pathway, from nociceptor transduction through spinal processing to cortical perception, emphasizing how inflammation and peripheral sensitization reshape excitability. Historically serendipitous, pain drug discovery now prioritizes molecular precision. Most approved chronic pain therapies act in the CNS and are limited by modest efficacy and adverse effects. Nociceptor-enriched targets (NaV1.7\/1.8\/1.9; TRP channels) remain attractive, yet redundancy among NaV subtypes and the necessity of blocking targets at the correct anatomical sites complicate translation. Human genetics and multi-omics provide a powerful, unbiased engine for target discovery. Rare high-impact variants offer strong causal hypotheses, while common polygenic contributions illuminate broader susceptibility. Large biobanks increasingly reveal a mismatch between legacy pain targets and genetically supported candidates across neuronal and non-neuronal cells. Human DRG transcriptomics highlight NaV channel redundancy. Human in vitro electrophysiology and PK\/PD analyses show suzetrigine achieves ~90\u201395% NaV1.8 engagement, yet neurons can still fire unless additional channels are blocked. Species differences and drug distribution (including BBB\/PNS penetration and P-gp efflux) critically influence efficacy; centrally accessible blockade (e.g., for NaV1.7 or TRPA1) may be necessary to achieve robust analgesia, challenging peripherally restricted strategies. Osteoarthritis illustrates how obesity-driven metabolic inflammation, synovial immune activation, subchondral bone remodeling, and specific nociceptor subtypes converge to drive mechanical pain. Multi-omic integration across diseased human tissues can pinpoint causal processes and cell types, enabling more selective and safer target choices. I propose a practical framework for target validation that integrates: (i) rigorous human genetic support; (ii) cell-type and site-of-action mapping; (iii) human-relevant electrophysiology and PK\/PD with verified target engagement; (iv) species-appropriate models; (v) consideration of modality (small molecule, biologic, RNA, targeted protein degradation). Advancing genetically and anatomically aligned targets, tested at the right sites and exposures, offers the best path to genuinely effective, better-tolerated pain therapeutics.<\/jats:p>","DOI":"10.3390\/ijms27073035","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:32:47Z","timestamp":1774611167000},"page":"3035","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mapping the Extended Pain Pathway: Human Genetic and Multi-Omic Strategies for Next-Generation Analgesics"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1389-9521","authenticated-orcid":false,"given":"Ari-Pekka","family":"Koivisto","sequence":"first","affiliation":[{"name":"Orion Pharma, Orion Corporation, FI-20101 Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"ref_1","unstructured":"(2026, March 25). Center for Drug Evaluation and Research Application Number: 219209Orig1s000 Integrated Review. Journavx (Suzetrigine; VX 548), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/219209Orig1s000IntegratedR.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2209870","article-title":"Selective Inhibition of NaV1.8 with VX 548 for Acute Pain","volume":"389","author":"Jones","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_3","unstructured":"Vertex Pharmaceuticals (2026, March 25). Vertex Announces Results from Phase 2 Study of VX 993 for the Treatment of Acute Pain. Available online: https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-announces-results-phase-2-study-vx-993-treatment-acute."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cell.2009.09.028","article-title":"Cellular and molecular mechanisms of pain","volume":"139","author":"Basbaum","year":"2009","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41591-024-02839-5","article-title":"A multi-ancestry genetic study of pain intensity in 598,339 veterans","volume":"30","author":"Toikumo","year":"2024","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/j.pain.0000000000003785","article-title":"Genome wide association study of neuropathic pain phenotypes implicates loci involved in neural cell adhesion, channels, collagen matrix formation, and immune regulation","volume":"167","author":"Packer","year":"2026","journal-title":"Pain"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41586-025-08771-z","article-title":"Translational genomics of osteoarthritis in 1,962,069 individuals","volume":"641","author":"Hatzikotoulas","year":"2025","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"fcad037","DOI":"10.1093\/braincomms\/fcad037","article-title":"Investigating genotype phenotype relationship of extreme neuropathic pain disorders in a UK national cohort","volume":"5","author":"Themistocleous","year":"2023","journal-title":"Brain Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/brain\/awab359","article-title":"Genome-wide analysis identifies impaired axonogenesis in chronic overlapping pain conditions","volume":"145","author":"Khoury","year":"2022","journal-title":"Brain"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-024-07316-0","article-title":"Refining the impact of genetic evidence on clinical success","volume":"629","author":"Minikel","year":"2024","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Newton, G.W., Charman, C., Nickerson, A.P., Phillips, K.G., Kless, A., Dunham, J.P., and Pickering, A.E. (2025). Carriers of SCN9A variants linked to inherited and acquired pain syndromes show no alteration in the prevalence of pain or analgesic usage in the UK Biobank cohort. medRxiv.","DOI":"10.1101\/2025.03.12.25323817"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13073-023-01253-9","article-title":"A phenome wide scan reveals convergence of common and rare variant associations","volume":"15","author":"Zhou","year":"2023","journal-title":"Genome Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"eadj9173","DOI":"10.1126\/sciadv.adj9173","article-title":"Harmonized cross-species cell atlases of trigeminal and dorsal root ganglia","volume":"10","author":"Bhuiyan","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/s41593-024-01794-1","article-title":"Leveraging deep single soma RNA sequencing to explore the neural basis of human somatosensation","volume":"27","author":"Yu","year":"2024","journal-title":"Nat. Neurosci."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bhuiyan, S.A., Nagi, S.S., Sankaranarayanan, I., Semizoglou, E., Usoskin, D., Yang, L., Yu, H., Arendt-Tranholm, A., Bertels, Z., and Bhatia, P. (2025). A Reference Atlas of the Human Dorsal Root Ganglion. bioRxiv.","DOI":"10.1101\/2025.11.05.686654"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.pain.2014.03.022","article-title":"Primary afferent input critical for maintaining spontaneous pain in peripheral neuropathy","volume":"155","author":"Haroutounian","year":"2014","journal-title":"Pain"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zhang, C.J., Ji, M.J., Zhou, X.L., Li, S., Xu, P.F., Wu, H., Chen, Q., Zhao, J., Chen, X.Z., and Cox, J.J. Nav1.5 in the dorsal root ganglion plays a crucial role in mechanical hypersensitivity, Brain 2026, online ahead of print.","DOI":"10.1093\/brain\/awaf438"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41572-025-00594-6","article-title":"Osteoarthritis","volume":"11","author":"Tang","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41584-019-0364-x","article-title":"Tendon and ligament mechanical loading in the pathogenesis of inflammatory arthritis","volume":"16","author":"Gracey","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13075-017-1229-9","article-title":"Synovitis in osteoarthritis: Current understanding with therapeutic implications","volume":"19","author":"Mathiessen","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Newton, M.D., Swahn, H., Orange, D.E., Lesnak, J.B., Price, T.J., Malfait, A.M., Miller, R.E., Lotz, M.K., RE JOIN Consortium Investigators, and Maerz, T. (Osteoarthr. Cartil., 2025). Cross platform transcriptomic data integration identifies an overactive neuro immune signature in human osteoarthritis synovium, Osteoarthr. Cartil., in press.","DOI":"10.1016\/j.joca.2025.08.013"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13075-021-02422-0","article-title":"Association of subchondral bone marrow lesion localization with weight bearing pain in people with knee osteoarthritis: Data from the Osteoarthritis Initiative","volume":"23","author":"Aso","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13075-024-03457-9","article-title":"Acute systemic macrophage depletion in osteoarthritic mice alleviates pain related behaviors and does not affect joint damage","volume":"26","author":"Geraghty","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"E1672","DOI":"10.1503\/cmaj.220952","article-title":"Metformin use and associated risk of total joint replacement in patients with type 2 diabetes: A population based matched cohort study","volume":"194","author":"Zhu","year":"2022","journal-title":"CMAJ"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41586-023-06888-7","article-title":"Nav1.7 as a chondrocyte regulator and therapeutic target for osteoarthritis","volume":"625","author":"Fu","year":"2024","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"ENEURO.0409","DOI":"10.1523\/ENEURO.0409-21.2022","article-title":"The Antidiabetic Drug Metformin Regulates Voltage Gated Sodium Channel NaV1.7 via the Ubiquitin Ligase NEDD4 2","volume":"9","author":"Deftu","year":"2022","journal-title":"Eneuro"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e197583","DOI":"10.1172\/JCI197583","article-title":"The cell type specific genetic architecture of chronic pain in brain and dorsal root ganglia","volume":"135","author":"Toikumo","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/14728222.2024.2416961","article-title":"Targeting the TRPV1 pain pathway in osteoarthritis of the knee","volume":"28","author":"Mobasheri","year":"2024","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.pain.2014.06.017","article-title":"Human sensory neurons: Membrane properties and sensitization by inflammatory mediators","volume":"155","author":"Davidson","year":"2014","journal-title":"Pain"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00656997","article-title":"Improved patch clamp techniques for high resolution current recording from cells and cell free membrane patches","volume":"391","author":"Hamill","year":"1981","journal-title":"Pflug. Arch."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e2503570122","DOI":"10.1073\/pnas.2503570122","article-title":"Modulation of human dorsal root ganglion neuron firing by the Nav1.8 inhibitor suzetrigine","volume":"122","author":"Stewart","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e2507342122","DOI":"10.1073\/pnas.2507342122","article-title":"Nav1.8: Intrinsic limits on the functional effect of abrogation in DRG neurons","volume":"122","author":"Vasylyev","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1152\/jn.00113.2015","article-title":"Human Na(v)1.8: Enhanced persistent and ramp currents contribute to distinct firing properties of human DRG neurons","volume":"113","author":"Han","year":"2015","journal-title":"J. Neurophysiol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Palomino, S.M., Gabriel, K.A., Koduri, A., Khan, I., Rahman, S.A., Horton, P., Khan, T., Cervantes, A., Funk, G., and Shiers, S. (2026). Nav1.8 mediates peripheral-to-central nociceptive transmission independently of central presynaptic mechanisms in human DRG-spinal cord circuits. bioRxiv.","DOI":"10.64898\/2026.02.27.708640"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/j.pain.0000000000001227","article-title":"Efficacy of the Nav1.7 blocker PF 05089771 in a randomised, placebo controlled, double blind clinical study in subjects with painful diabetic peripheral neuropathy","volume":"159","author":"McDonnell","year":"2018","journal-title":"Pain"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/j.pain.0000000000003823","article-title":"Intrathecal administration of the Nav1.7 inhibitor PF 05089771 produces rapid and side effect free analgesia in mice","volume":"167","author":"Zhou","year":"2025","journal-title":"Pain"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Malange, K.F., Lemes, J.B.P., Noble, B., Anchondo, Y., Urbina, C.M., Jadhav, S., Dochnal, S., Kambalimath, C., Alvarez, P., and Fitzsimmons, B. (2025). Analgesic actions of Intrathecal NaV 1.7 antisense in rats: Loss of antagonist channel 2 binding, message depletion, and neuraxial distribution of oligonucleotide. bioRxiv.","DOI":"10.1101\/2025.05.19.654680"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1161\/CIRCULATIONAHA.123.067331","article-title":"Autonomic Dysfunction Linked to Inhibition of the Nav1.7 Sodium Channel","volume":"149","author":"Regan","year":"2024","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.117.245613","article-title":"Drug Distribution into Peripheral Nerve","volume":"365","author":"Liu","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0092-8674(03)00158-2","article-title":"ANKTM1, a TRP like channel expressed in nociceptive neurons, is activated by cold temperatures","volume":"112","author":"Story","year":"2003","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1152\/physrev.00005.2019","article-title":"Mammalian Transient Receptor Potential TRPA1 Channels: From Structure to Disease","volume":"100","author":"Talavera","year":"2020","journal-title":"Physiol. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/00001756-200506210-00015","article-title":"TRPA1 and TRPM8 activation in humans: Effects of cinnamaldehyde and menthol","volume":"16","author":"Namer","year":"2005","journal-title":"Neuroreport"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.neuron.2010.04.030","article-title":"A gain of function mutation in TRPA1 causes familial episodic pain syndrome","volume":"66","author":"Kremeyer","year":"2010","journal-title":"Neuron"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1097\/j.pain.0000000000003570","article-title":"Preclinical and clinical evaluation of a novel TRPA1 antagonist LY3526318","volume":"166","author":"Broad","year":"2025","journal-title":"Pain"},{"key":"ref_45","first-page":"1497","article-title":"Clinical proof of concept results with a novel TRPA1 antagonist (LY3526318) in 3 chronic pain states","volume":"166","author":"Wilbraham","year":"2024","journal-title":"Pain"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.1113\/JP286407","article-title":"Activation of TRPA1 and TRPM3 triggers Ca2+ waves in central terminals of sensory neurons and facilitates synaptic activity in the spinal dorsal horn","volume":"603","author":"Andrianov","year":"2025","journal-title":"J. Physiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bcpt.12138","article-title":"TRPA1: A transducer and amplifier of pain and inflammation","volume":"114","author":"Koivisto","year":"2014","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.pain.2009.12.002","article-title":"The involvement of the transient receptor potential A1 (TRPA1) in the maintenance of mechanical and cold hyperalgesia in persistent inflammation","volume":"148","author":"Meotti","year":"2010","journal-title":"Pain"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.pain.2010.11.031","article-title":"Spinal transient receptor potential ankyrin 1 channel contributes to central pain hypersensitivity in various pathophysiological conditions in the rat","volume":"152","author":"Wei","year":"2011","journal-title":"Pain"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue based map of the human proteome","volume":"347","author":"Fagerberg","year":"2015","journal-title":"Science"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.neuroscience.2017.12.009","article-title":"Oxidative Stress in the Amygdala Contributes to Neuropathic Pain","volume":"387","author":"Sagalajev","year":"2018","journal-title":"Neuroscience"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41583-021-00536-7","article-title":"Innovations and advances in modelling and measuring pain in animals","volume":"23","author":"Sadler","year":"2022","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1097\/j.pain.0000000000002680","article-title":"Automated preclinical detection of mechanical pain hypersensitivity and analgesia","volume":"163","author":"Zhang","year":"2022","journal-title":"Pain"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"101145","DOI":"10.1016\/j.crmeth.2025.101145","article-title":"A machine learning tool with light based image analysis for automatic classification of 3D pain behaviors","volume":"5","author":"Barkai","year":"2025","journal-title":"Cell Rep. Methods"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13041-025-01253-3","article-title":"Pharmacological inhibition of NaV1.8 by suzetrigine reveals potent analgesic potential without tolerance development in mice","volume":"18","author":"Ali","year":"2025","journal-title":"Mol. Brain"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/nar\/gkac1198","article-title":"Optimized high throughput screening of non coding variants identified from genome wide association studies","volume":"51","author":"Morova","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"R73","DOI":"10.1093\/hmg\/ddac198","article-title":"Demystifying non coding GWAS variants: An overview of computational tools and methods","volume":"31","author":"Schipper","year":"2022","journal-title":"Hum. Mol. Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd.2017.244","article-title":"Impact of a five dimensional framework on R&D productivity at AstraZeneca","volume":"17","author":"Morgan","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1093\/hmg\/ddq365","article-title":"Loss-of-function variants in the genomes of healthy humans","volume":"19","author":"MacArthur","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41467-023-38542-1","article-title":"Molecular mechanism of hyperactivation conferred by a truncation of TRPA1","volume":"14","author":"Bali","year":"2023","journal-title":"Nat. Commun."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/3035\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T04:11:40Z","timestamp":1774843900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/3035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":60,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ijms27073035"],"URL":"https:\/\/doi.org\/10.3390\/ijms27073035","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}